Key Focus Points

• Biosimilar insulins are novel insulin products that are modified from the original insulin but intended to be clinically equivalent to the existing licensed biological product.

• There are many technical challenges to developing a biosimilar insulin that will reach clinical use, including establishing the equivalence of the novel product and the licensed comparator.

• Different methods are available for measuring the clinical equivalence of a biosimilar product to a licensed reference insulin, but the euglycemic clamp procedure is widely recognized as the preferred method.

• The European Medical Agency (EMA) has issued regulatory guidelines for the development of biosimilar insulins that emphasize pharmacokinetic/pharmacodynamic studies rather than efficacy evaluations. In the United States, biosimilar insulins are currently covered by the Food and Drug Administration’s (FDA) 505(b)(2) pathway permitting evaluation of the reference product.
Introduction

Insulin is used in the treatment of all patients with type 1 diabetes and in a substantial proportion of those with type 2 diabetes. Nonetheless, optimal insulin replacement remains a therapeutic challenge. Recombinant insulin is the mainstay of insulin therapy. When a licensed insulin product reaches the end of its patent life the market opens for biosimilar products - also known as follow-on biologics - which are modifications of the originator insulin that are intended to be clinically equivalent to the licensed product.

Biosimilar insulins are regarded as an attractive therapeutic option. However, there are numerous technical challenges in producing and manufacturing a biosimilar insulin. Given the time and expense that is required to develop a biosimilar insulin, it is imperative that the clinical development programs for these compounds are carefully managed at all stages.

As of 2015, only one biosimilar insulin has been approved in the European Union and none in the United States (US).

Challenges for Developing Insulin Biosimilars

The development of a biosimilar insulin presents numerous challenges that are not encountered when producing a small molecule generic drug:

1. Insulin is a protein with a large and complex molecular structure (primary, secondary, tertiary, quaternary), even minor alterations of which may affect its function. The manufacturing process of biosimilar insulins can lead to products with different characteristics than the originator insulins. Thus, biosimilar human insulin and insulin analogs can never be assumed to be identical copies of the innovator products.

2. Manufacturing of biosimilar insulins is highly complicated and uses biological systems with inherent variability; these considerations are challenging to regulate and pose potential concerns with regard to quality assurance and batch consistency.

3. Accordingly, there is potential for biosimilar insulins to differ from reference medicinal products. Even minor changes to the protein can impact the pharmacokinetic and pharmacodynamic properties of the biosimilar insulin compared to the reference licensed insulin. The therapeutic index for insulin in clinical practice is narrow and even minor alterations in the pharmacokinetic and pharmacodynamic properties of a biosimilar insulin could affect the benefit-to-risk equation.

4. Immunogenicity is a concern in the manufacturing of biosimilar insulins, in part because of the reliance on living organisms during production. The presence of neutralizing antibodies that block the activity of the product should be carefully assessed and a risk management program for potentially autoimmune reactions is required. However, clinically important immunogenicity in patients treated with insulin is rare and so large and long-term observational studies are required to detect this safety signal; it is expected that biosimilar insulins will have similarly low immunogenicity, but this must be reliably confirmed for each biosimilar product.

5. Delivery device related issues also need to be considered. The design of the device used to administer a biosimilar insulin is critical. The delivery device can affect the accuracy of dosing. The European Medical Agency (EMA) requires that device compatibility be demonstrated.
Regulatory Pathways for Biosimilar Products

Once a biosimilar product has been developed it must go through a regulatory approval process. Given that the manufacturing process leading to slight variations between biosimilar insulins and reference insulin products is proprietary, regulatory agencies have adopted the strategy of assessing the degree to which the action of the two products is similar to ensure clinical equivalence.

To meet the stringent regulatory requirements in Europe and the U.S., manufacturers are required to undertake structured clinical development programs. Europe and the U.S. are considered “tight” regulatory markets compared to other countries. The rigorous requirements of the U.S. and European regulatory authorities towards biosimilars reflect the complex nature of these biopharmaceutical products as well as the proprietary manufacturing process. The regulatory requirements for approval of biosimilar insulins differ in specifics between the EMA and the FDA, but both include evaluation of pharmacodynamic properties and immunogenicity.

European Medical Agency

The most recent EMA guidelines for biosimilar insulins were issued in 2014 in draft form (updated in 2015). EMA guidance on recombinant human insulin and insulin analogs considers the design of glucose clamp studies and approaches to pharmacokinetic/pharmacodynamic data analysis and interpretation as well as safety studies, the latter focusing on immunogenicity. The EMA also requires that device compatibility be demonstrated.

Preclinical studies required by the EMA include in-vitro pharmacodynamic evaluation, in-vitro affinity bioassays, and assays for binding to insulin and insulin-like growth factor-1 receptors.

For the required clinical studies, the euglycemic glucose clamp plays a crucial role in the evaluation of the pharmacodynamics of a biosimilar insulin. The EMA’s position is that the sensitivity to detect differences between insulin products is higher for euglycemic clamp pharmacodynamic studies than for clinical efficacy trials; the latter are considered only supportive in this context. The EMA guidance provides extensive information on practical considerations for comparative glucose clamp studies, including the selection of subjects and pharmacokinetic/pharmacodynamic assessments. The glucose clamp study should include at least one single-dose crossover study design to be performed in patients with type 1 diabetes.

Manufacturers of biosimilar insulins are required to present a risk management plan in accordance with current EU legislation and pharmacovigilance guidelines detailing how safety concerns, including those pertaining to the reference product, will be addressed post-marketing.

Food and Drug Administration

The FDA approval process for biosimilars is covered under section 351(k) of the Public Health Service Act. The requirements are described in four draft documents issued between 2012 and 2014. Currently, insulins are not covered by the FDA biosimilar guideline. Rather, they may be approved through the FDA’s 505(b)(1) (traditional new drug application [NDA]), 505(b)(2) (abbreviated NDA), or 505(j) (generic drug approval) regulatory pathways. The 505(b)(2) pathway permits evaluation of the reference product. After April 2020 the status of insulin will be changed to that of a biosimilar, and the approval process will be the responsibility of the Center for Biologics Evaluation and Research. The final guidance for developing biosimilars outlines a stepwise approach with emphasis on the desirability of frequent consultations with the FDA, and extensive pharmacokinetic/pharmacodynamic studies. The key steps, which may take place in parallel, include: 1) structural and functional characterization of the proposed biosimilar product compared to the reference product; 2) toxicity studies in animal studies; and 3) clinical studies of pharmacokinetics, pharmacodynamics, and immunogenicity.
As in the case of the EMA, the FDA guidance considers pharmacokinetic/pharmacodynamic assessments to be more important than clinical efficacy when assessing similarity to a reference product.

**Pharmacokinetic and Pharmacodynamic Studies**

Bringing a biosimilar insulin to market presents a higher hurdle than that required for a generic small molecular weight drug; having a well-designed clinical trial program helps facilitate the process.

Table 1. Study design considerations in insulin analogue time-action profile studies: selection of study population

<table>
<thead>
<tr>
<th>Type 1 diabetes</th>
<th>Advantage of having no/negligible endogenous insulin secretion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Type 2 diabetes</td>
<td>Largest clinically relevant population. However, variable endogenous insulin secretion may confound results</td>
</tr>
<tr>
<td>Healthy volunteers</td>
<td>Endogenous insulin secretion should be suppressed by either (a) clamping at a target blood glucose concentration below fasting levels or (b) continuous intravenous administration of an appropriate dose of insulin</td>
</tr>
</tbody>
</table>

Given the regulatory emphasis on pharmacokinetic and pharmacodynamic studies rather than clinical efficacy, it is critical that these studies be technically sound and integrated within the overall clinical development program for the biosimilar product. Partnering with experienced clinical study sites can provide valuable support in terms of study design (including selection of subjects: Table 1), technical expertise (especially in with the euglycemic clamp technique: Table 2), and preparation of regulatory submissions. The EMA guidance may be used as a starting reference point for the design of clinical studies as it is both rigorous and has been widely applied.

**Pharmacokinetic Studies**

The pharmacokinetics of a drug describes its concentration, along with those of its metabolites, in the body over time. In the case of insulin biosimilars, in order to meet regulatory requirements appropriate biosimilar-specific assays must be used to reliably measure the blood levels of the molecules in question.

**Pharmacodynamic Studies**

Of the available methods for quantifying insulin action the euglycemic glucose clamp technique is regarded as the reference method for the development of new diabetes drugs (Table 1).
Table 2. Assessing the pharmacodynamic properties of insulin biosimilars and reference insulins using the time-action profile glucose euglycemic clamp technique

<table>
<thead>
<tr>
<th>Method</th>
<th>Measure</th>
<th>Advantages</th>
<th>Disadvantages</th>
<th>Value in Biosimilar Insulin Development</th>
</tr>
</thead>
<tbody>
<tr>
<td>Euglycemic clamp: Insulin is administered by subcutaneous injection/inhalation, etc. Hypertonic glucose is infused intravenously at a variable rate to maintain plasma glucose at euglycemia</td>
<td>Maximal glucose infusion rate (GIR_max); time to GIR_max (t_max); area under the curve (AUC_0-7)</td>
<td>Yields simultaneous detailed pharmacodynamic and pharmacokinetic data</td>
<td>Labor intensive; requires skilled technical staff; assessment of ultra-long acting insulins has limitations</td>
<td>Clamp-derived time-action profiles for insulin and biosimilar insulins are required by US and European regulators for market approval of new insulins</td>
</tr>
</tbody>
</table>


Current and Future Status of Insulin Biosimilars

Biosimilar insulins currently under development being include basal and prandial insulins. Because biosimilars and their reference molecules are not identical, confirmation of biosimilarity does not necessarily imply interchangeability in clinical practice. The latter consideration is subject to state and/or national regulations that are independent of the drug approval process. Whether the current regulatory requirements will provide sufficient confidence among physicians and their patients to switch to biosimilar insulins is unclear given the expected paucity of clinically relevant data in areas such as glucose control and nocturnal hypoglycemia. Device compatibility is also a consideration.

Conclusions

Many of the challenges in the development of biosimilar insulins are inherent to the product, and include the complexity of the insulin protein and the use of living organisms in the manufacturing process. The regulatory requirements for biosimilar insulins emphasize the use of pharmacokinetic and pharmacodynamic studies to establish clinical equivalence. While there are many methods of assessing pharmacodynamic equivalence, the euglycemic clamp procedure is the preferred method because it is sensitive, robust, and reproducible.

Looking Ahead

The technical and regulatory challenges associated with developing a biosimilar insulin products mean that the barrier to market entry is higher than other generic drugs. As the global regulatory climate continues to evolve and become more harmonized staying current on the regulatory guidelines will be crucial to obtaining approval in multiple markets. A comprehensive clinical development program that incorporates the required pharmacokinetic/pharmacodynamic and safety studies is required. As more insulin biosimilars approach clinical trials, it will be necessary to ensure that the study populations, methods of assessing similarity, and safety assessments are comparable between studies. Working partnerships between biosimilar producers and experienced clinical study sites can provide valuable expertise to ensure a well-designed program and technically sound study data.
Further Reading


About the Authors

Andrew J Krentz, MD, FRCP
ProSciento, Inc., Senior Research Fellow

As Senior Research Fellow at ProSciento, Prof. Krentz’s research involves investigator-initiated research in diabetes and cardiometabolic therapies. In addition to original articles, reviews and book chapters he has authored or edited a number of textbooks on diabetes and cardiovascular disease including and The Metabolic Syndrome and Cardiovascular Disease (2007), Drug Therapy for Type 2 Diabetes (2013) and Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development (2015). He is Professor of Endocrinology & Metabolism at the University of Buckingham, UK. Prof. Krentz serves on the editorial boards of several scientific journals and is founding Editor-in-Chief of Cardiovascular Endocrinology.

Marcus Hompesch, MD
ProSciento, Inc., Chief Executive Officer

Dr. Hompesch's is a highly regarded expert in early phase clinical trial design for diabetes, obesity and related metabolic drug and device development. He is also a founder of ProSciento, the leading CRO exclusively focused on metabolic diseases and one of the few CROs actively conducting clinical research and biomarker validation studies using imaging and biopsy methods to detect progressive NASH in NAFLD and diabetes patients for therapeutic development. Dr. Hompesch is the author of more than 85 peer-reviewed publications and editorials and is a regularly invited speaker at medical conferences. He is also an editor and co-author of a new textbook Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development (2015).
About ProSciento Focus Papers
ProSciento’s Focus Papers narrow in on one area of expertise and are authored by key scientific thought leaders. Contact us for additional Focus Papers or follow us on LinkedIn to be notified of new papers.

Contact Us
Business Development and Scientific Services
US and Canada toll free +1 (866) 245-5445
International +1 (619) 419-2038
bd@prosciento.com
www.prosciento.com

ProSciento, Inc.
855 3rd Avenue Suite 3340
Chula Vista, CA 91911. USA

© 2016 ProSciento, Inc.